Form 4: Denali Therapeutics Director Vicki L. Sato Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Vicki L. Sato sold 1,666 shares of Denali Therapeutics Inc. (DNLI) common stock at a price of $18.29 per share on April 15, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 15, 2024, Vicki L. Sato, a director of Denali Therapeutics Inc., sold 1,666 shares of common stock.
- The sale was executed at a price of $18.29 per share.
- The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 27, 2023.
- Following the transaction, Sato beneficially owns 118,043 shares of Denali Therapeutics Inc., which includes 4,216 unvested Restricted Stock Units (RSUs).
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to an insider share sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Industry Context
Sales by insiders are common and often pre-planned using 10b5-1 trading plans to avoid accusations of trading on material non-public information. The filing provides transparency into the transactions of company insiders.
Stakeholder Impact
- The sale of shares by a director could have a minor impact on shareholder sentiment, but the existence of a 10b5-1 trading plan mitigates concerns about insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-09-27 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-04-15 | Date of the transaction (sale of shares). |
| 2024-04-17 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.